ConductScience.org, home

Gene · 104

ADARB1: adenosine deaminase RNA specific B1

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. ADARB1: adenosine deaminase RNA specific B1. Genes, record 104. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/104

On this page

Gene

Symbol
ADARB1
HGNC
Name
adenosine deaminase RNA specific B1
HGNC
NCBI Gene ID
104
NCBI Gene
HGNC ID
HGNC:226
HGNC
Ensembl
ENSG00000197381
NCBI Gene
Aliases
ADAR2, ADAR2a, ADAR2a-L1, ADAR2a-L2, ADAR2a-L3, ADAR2b, ADAR2c, ADAR2d, ADAR2g, DRABA2, DRADA2, NEDHYMS, RED1, hRED1
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
P78563Double-stranded RNA-specific editase 174113Ensembl, GeneID, HGNC

Source UniProt

Patents55

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
US 12601751 B22026-04-149P78563Espacenet
EP 4720289 A12026-04-08207P78563Espacenet
JP 2026004568 A2026-01-1436641P78563Espacenet
JP 2026004568 A2026-01-1436645P78563Espacenet
JP 2026004568 A2026-01-1436646P78563Espacenet
EP 4650780 A22025-11-197816P78563Espacenet
EP 4641201 A22025-10-297903P78563Espacenet
EP 4608979 A12025-09-03876P78563Espacenet
JP 2025517969 A2025-06-127903P78563Espacenet
JP 2025517970 A2025-06-127816P78563Espacenet

1 to 10 of 55

See all 55 patents

Drugs0

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

None in this release.

Trials0

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

None in this release.

NIH grants1,355

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitleADARB1 papersNewest fiscal year
P30CA010815Consolidated Basic Cancer Research Program182025
P30CA016672Cancer Center Support Grant112025
P30CA042014Cancer Center Support Grant92025
R35GM141907Defining and Controlling Protein-RNA interactions in editing and interference pathways72025
P30CA008748Cancer Center Support Grant52025
K12GM068524San Diego IRACDA Scholars Program42025
P30CA016058Cancer Center Support Grant42025
T32CA009171Training Program in Basic Cancer Research42025
P30CA015083Mayo Clinic Comprehensive Cancer Center Support Grant32025
P30CA051008Georgetown University Lombardi Comprehensive Cancer Center Support Grant32025

1 to 10 of 1,355Source NIH's project files

See all 1,355 nih grants

Papers2,137

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
ADAR1 and ADAR2 Expression in the Thoracic Aortic Wall Correlates with Aneurysm Severity and Dissection Risk: Insights into A-to-I RNA Editing Dysregulation in Marfan Syndrome-Derived vSMCs.Int J Mol Sci202642794678PubTator, text miningPubMed
Dynamic reprogramming and A-to-I RNA editing in neutrophils in response to tumor induction.J Biol Chem202642754162PubTator, text miningPubMed
Context-dependent modulation of the TAK1-MAPK axis by ginsenoside-based formulations along the NAFLD-HCC continuum.J Ginseng Res202642718885PubTator, text miningPubMed
A-to-I editing modifies the target and role of miR-376a-3p in papillary thyroid cancer.3 Biotech202642688527PubTator, text miningPubMed
ADAR-mediated RNA editing in CNS disorders: from pathogenic mechanisms to therapeutic opportunities.Cell Mol Biol Lett202642576199PubTator, text miningPubMed
New insight into RNA biomarkers in neuropathic pain: a clinician-neuroscientist roadmap to translational testing and treatment monitoring a clinical review.Front Pain Res (Lausanne)202642534835PubTator, text miningPubMed
A contextual activity score (CAS) for inferring ADAR-associated transcriptional activity across RNA-seq, single-cell, and spatial transcriptomics.Comput Methods Programs Biomed202642526067PubTator, text miningPubMed
A reduction in A-to-I RNA editing by ADAR disrupts Pumilio-mediated inhibition of MAPK signaling to drive intestinal stem cell aging.Sci Signal202642520108PubTator, text miningPubMed
ADAR2-Mediated RNA Editing Promotes TDP-43 Nuclear Export and Alters RNA Binding.bioRxiv202642395430PubTator, text miningPubMed
The regulatory mechanism and clinical significance of RNA editing in prostate cancer.Curr Urol202642368672PubTator, text miningPubMed

1 to 10 of 2,137

See all 2,137 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/104

GET https://conductscience.org/api/genes/v1/104/patents?page=2